This chapter describes the direct thrombin inhibitor, dabigatran etexilate, and P2Y1 12 platelet inhibitor, ticagrelor, used as anticoagulants. It discusses general information, the discovery, and the chemical process of these two representative drugs. For the chemical process of dabigatran etexilate, ...
Updated expert consensus statement on platelet functionand genetic testing for guiding P2Y12 receptor inhibitor treatment inpercutaneous coronary intervention. JACC Cardiovasc Interv 2019;12:1521–https://doi.org/10.1016/j.jcin.201...
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this ...
Oral P2Y12 inhibitors (P2Y12-I) are commonly used antiplatelet drugs in patients with end-stage kidney disease (ESKD) on chronic dialysis. Although gaps in prescription refills are quite common in patients with ESKD, it remains unclear whether P2Y12-I prescription refill patterns are associated wi...
The platelet inhibitor of choice, the optimal time of initiation and the duration of treatment depend on the indication for therapy and patient characteristics. In recent years, bleeding has been identified as an important risk factor for adverse outcomes and has led to a renewed emphasis on indiv...
Based on several randomized clinical trials, potent P2Y12 inhibitors, such as ticagrelor and prasugrel, have become the standard of care for the treatment of AMI, offering more potent and consistent platelet inhibition compared to clopidogrel [1,2,3]. Among AMI patients, 5–10% of patients ...
Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial[J]. JAMA, 2019,321(24):2428-2437. DOI: 10.1001/jama.2019.8146 . 返回引文位置Google Scholar 百度学术 万方...
This latest registry analysis, however, suggests early administration of these drugs still has a role to play. “We found that the benefits are time dependent, and we found that the benefit in a reduction of a MACE consists of all-cause mortality, myocardial infection, stroke, and definite st...
platelet inhibitors under clinical development (the P2Y12 antagonist selatogrel and the GPIIb-IIIa antagonist zalunfiban) that may be amenable to pre-hospital treatment of STEMI patients. Platelet reactivity was assessed at inhibitor concentrations that represent clinically relevant levels of platelet ...
Non-Steroidal Anti-Inflammatory Drugs OTC: Over the Counter Medication PCI: Percutaneous Coronary Intervention PLT: Platelet RCT: Randomized Clinical Trial PRP: Platelet Rich Plasma Tica: Ticaloguard References El-Adawy AH, Elkhawaga G, Elraheem SA, Mahfouz E. Impact of socioeconomic sta...